Cambrian Biopharma

Cambrian Biopharma is a clinical-stage pharmaceutical company developing treatments for age-related diseases. Cambrian Biopharma is a distributed company (DisCo) with a portfolio of pipeline programs to address biological aspects of aging in order to create preventative treatments and improve the quality of life for those suffering from age-related disease. It is also partnering with academic institutions across the US and Europe to create Cambrian Affiliate Companies (Affiliates) with the aim of connecting academic discovery and drug development.

Cambrian's mission is:

..To improve the quality of life for people all over the world. To do this, we are developing medicines to target the mechanistic drivers of aging, first as treatments and then as preventive medicines.

The company was founded in 2019 by James Peyer, Sebastian Brunemeier, Christian Angermayer, and Paul Farr. James Peyer serves as the company's chief executive officer.

Cambrian Biopharma has a variety of programs in its pipeline funded and directed by Cabrian to target various biological drivers of aging. PipeCos include the following:

• Amplifier Therapeutics: Peripherally restricted pan-AMPK activator for the treatment of cardiometabolic diseases

• Tornado Therapeutics: mTOR inhibitors for extended healthspan

• Telos Biotech: Senescence and exhaustion

• Oviva Therapeutics: Women's health and aging

• Isterian Biotech: Fibrosis

• Vita Therapeutics: Cellular engineering